ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $79.00.

ANIP has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Guggenheim boosted their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,300 shares of company stock worth $584,869 in the last quarter. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares during the last quarter. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after acquiring an additional 9,500 shares during the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after buying an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares in the last quarter. Finally, Mizuho Markets Americas LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $11,670,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 4.4 %

NASDAQ ANIP opened at $61.40 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock’s 50 day moving average is $57.86 and its two-hundred day moving average is $58.07. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -111.64 and a beta of 0.63. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.